JP6042455B2 - 免疫原性組成物の調製方法 - Google Patents

免疫原性組成物の調製方法 Download PDF

Info

Publication number
JP6042455B2
JP6042455B2 JP2014555364A JP2014555364A JP6042455B2 JP 6042455 B2 JP6042455 B2 JP 6042455B2 JP 2014555364 A JP2014555364 A JP 2014555364A JP 2014555364 A JP2014555364 A JP 2014555364A JP 6042455 B2 JP6042455 B2 JP 6042455B2
Authority
JP
Japan
Prior art keywords
meningococcal
conjugate
serogroup
saccharide
immunogenic composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014555364A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015509111A5 (cg-RX-API-DMAC7.html
JP2015509111A (ja
Inventor
ヴィニヤック カプレ、サブハッシュ
ヴィニヤック カプレ、サブハッシュ
シャンカー ピサール、サンブハジ
シャンカー ピサール、サンブハジ
Original Assignee
セラム インスティチュート オブ インディア プライベイト リミテッド
セラム インスティチュート オブ インディア プライベイト リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セラム インスティチュート オブ インディア プライベイト リミテッド, セラム インスティチュート オブ インディア プライベイト リミテッド filed Critical セラム インスティチュート オブ インディア プライベイト リミテッド
Publication of JP2015509111A publication Critical patent/JP2015509111A/ja
Publication of JP2015509111A5 publication Critical patent/JP2015509111A5/ja
Application granted granted Critical
Publication of JP6042455B2 publication Critical patent/JP6042455B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
JP2014555364A 2012-01-30 2013-01-29 免疫原性組成物の調製方法 Active JP6042455B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN281/MUM/2012 2012-01-30
IN281MU2012 2012-01-30
PCT/IB2013/050739 WO2013114268A1 (en) 2012-01-30 2013-01-29 Immunogenic composition

Publications (3)

Publication Number Publication Date
JP2015509111A JP2015509111A (ja) 2015-03-26
JP2015509111A5 JP2015509111A5 (cg-RX-API-DMAC7.html) 2016-02-25
JP6042455B2 true JP6042455B2 (ja) 2016-12-14

Family

ID=54259032

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014555364A Active JP6042455B2 (ja) 2012-01-30 2013-01-29 免疫原性組成物の調製方法

Country Status (17)

Country Link
US (1) US9198977B2 (cg-RX-API-DMAC7.html)
EP (1) EP2809349B1 (cg-RX-API-DMAC7.html)
JP (1) JP6042455B2 (cg-RX-API-DMAC7.html)
KR (1) KR101897317B1 (cg-RX-API-DMAC7.html)
CN (1) CN104302315B (cg-RX-API-DMAC7.html)
BR (1) BR112014018815B1 (cg-RX-API-DMAC7.html)
CA (1) CA2863178C (cg-RX-API-DMAC7.html)
DK (1) DK2809349T3 (cg-RX-API-DMAC7.html)
ES (1) ES2707294T3 (cg-RX-API-DMAC7.html)
HU (1) HUE040914T4 (cg-RX-API-DMAC7.html)
MX (1) MX354103B (cg-RX-API-DMAC7.html)
PT (1) PT2809349T (cg-RX-API-DMAC7.html)
RU (1) RU2634405C2 (cg-RX-API-DMAC7.html)
SG (1) SG11201404447WA (cg-RX-API-DMAC7.html)
SI (1) SI2809349T1 (cg-RX-API-DMAC7.html)
TR (1) TR201900778T4 (cg-RX-API-DMAC7.html)
WO (1) WO2013114268A1 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2283857T3 (da) 2005-06-27 2019-10-28 Glaxosmithkline Biologicals Sa Vaccinesammensætning omfattende konjugerede native N. Meningitidis kapselpolysaccharider
MX364644B (es) * 2012-11-21 2019-05-03 Serum Inst India Ltd Produccion de altos rendimientos de polisacaridos bacteriales.
WO2015029056A1 (en) * 2013-08-24 2015-03-05 Bharat Biotech International Limited A bacterial vaccine and methods for manufacture thereof
EP2921856B1 (en) 2014-03-18 2016-09-14 Serum Institute Of India Private Limited A quantitative assay for 4-pyrrolidinopyridine (4-ppy) in polysaccharide-protein conjugate vaccines
EP3302542A4 (en) * 2015-06-08 2019-04-10 Serum Institute Of India Private Limited METHOD FOR IMPROVING ADSORPTION OF POLYSACCHARIDE PROTEIN CONJUGATES AND POLYVALENT VACCINE FORMULATION THEREOF
WO2017006349A1 (en) * 2015-07-04 2017-01-12 Bharat Biotech International Limited Polysaccharide vaccine formulations and processes for industrial production of bacterial polysaccharides
BR112018068523A2 (pt) * 2016-03-15 2019-01-22 Msd Wellcome Trust Hilleman Laboratories Pvt Ltd novos conjugados de polissacarídeo-proteína e processo para obter os mesmos
CN106110316A (zh) * 2016-06-27 2016-11-16 北京智飞绿竹生物制药有限公司 一种肺炎球菌结合物组合疫苗的制备方法
WO2018045286A1 (en) * 2016-09-02 2018-03-08 Sanofi Pasteur, Inc. Neisseria meningitidis vaccine
CN106397537B (zh) * 2016-10-13 2020-01-07 李红臣 一种高效快速的多糖蛋白结合疫苗纯化分析方法
GEP20227408B (en) 2017-05-05 2022-08-25 Serum Institute Of India Pvt Ltd Method for removal of impurities from bacterial capsular polysaccharide based preparations
RU2019142846A (ru) * 2017-06-27 2021-07-27 Мсд Веллком Траст Хиллеман Лабораторис Пвт. Лтд. Новая многовалентная вакцинная композиция на основе полисахаридно-белковых конъюгатов и ее состав
US20200353064A1 (en) * 2018-01-29 2020-11-12 Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. Novel meningococcal vaccine composition and process thereof
WO2019198096A1 (en) * 2018-04-11 2019-10-17 Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. Tetravalent meningococcal vaccine composition and process to prepare thereof
JOP20200214A1 (ar) 2019-09-03 2021-03-03 Serum Institute Of India Pvt Ltd تركيبات مولدة للمناعة ضد الأمراض المعوية وطرق لتحضيرها
MX2022003682A (es) 2019-09-27 2022-04-25 Pfizer Composiciones de neisseria meningitidis y metodos de las mismas.
WO2022035816A1 (en) 2020-08-10 2022-02-17 Inventprise, Llc Multivalent pneumococcal glycoconjugate vaccines containing emerging serotype 24f
CN118078981A (zh) * 2024-04-26 2024-05-28 成都康华生物制品股份有限公司 一种基于双蛋白载体的五价脑膜炎球菌多糖结合疫苗的制备方法及其产品

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2763244B1 (fr) * 1997-05-14 2003-08-01 Pasteur Merieux Serums Vacc Composition vaccinale multivalente a porteur mixte
WO2002000249A2 (en) * 2000-06-29 2002-01-03 Glaxosmithkline Biologicals S.A. Multivalent vaccine composition
GB0115176D0 (en) * 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
GB0130215D0 (en) * 2001-12-18 2002-02-06 Glaxosmithkline Biolog Sa Vaccine
CN103405761A (zh) * 2003-10-02 2013-11-27 诺华疫苗和诊断有限公司 多种脑膜炎球菌血清群的液体疫苗
DK2283857T3 (da) * 2005-06-27 2019-10-28 Glaxosmithkline Biologicals Sa Vaccinesammensætning omfattende konjugerede native N. Meningitidis kapselpolysaccharider
GB0513069D0 (en) * 2005-06-27 2005-08-03 Glaxosmithkline Biolog Sa Immunogenic composition
CA2621023C (en) * 2005-09-01 2019-07-02 Novartis Vaccines And Diagnostics Gmbh & Co. Kg Multiple vaccination including serogroup c meningococcus
ES2707499T3 (es) * 2005-12-22 2019-04-03 Glaxosmithkline Biologicals Sa Vacuna de conjugado de polisacárido neumocócico
GB0703369D0 (en) * 2007-02-21 2007-03-28 Health Prot Agency Compositions Comprising Capsular Polysaccharides and Their Use as Vaccines
DK2513056T3 (da) * 2009-12-17 2022-05-23 Serum Inst Of India Pvt Ltd Kemiske reagenser til aktivering af polysaccharider i fremstillingen af konjugatvacciner
BR112014029313A2 (pt) * 2012-05-22 2017-06-27 Novartis Ag conjugado de meningococos do sorogrupo x

Also Published As

Publication number Publication date
HUE040914T4 (hu) 2019-05-28
US20140377302A1 (en) 2014-12-25
EP2809349B1 (en) 2018-12-19
JP2015509111A (ja) 2015-03-26
CA2863178A1 (en) 2013-08-08
BR112014018815A8 (pt) 2017-07-11
US9198977B2 (en) 2015-12-01
CN104302315A (zh) 2015-01-21
WO2013114268A1 (en) 2013-08-08
KR20140123553A (ko) 2014-10-22
SI2809349T1 (sl) 2019-03-29
RU2634405C2 (ru) 2017-10-26
TR201900778T4 (tr) 2019-02-21
KR101897317B1 (ko) 2018-09-11
MX2014009250A (es) 2015-03-19
CA2863178C (en) 2021-04-06
BR112014018815B1 (pt) 2022-07-12
DK2809349T3 (da) 2019-02-18
ES2707294T3 (es) 2019-04-03
BR112014018815A2 (cg-RX-API-DMAC7.html) 2017-06-20
SG11201404447WA (en) 2014-08-28
EP2809349A1 (en) 2014-12-10
CN104302315B (zh) 2018-02-06
RU2014134288A (ru) 2016-03-20
PT2809349T (pt) 2019-02-01
MX354103B (es) 2018-02-13
EP2809349A4 (en) 2015-08-26

Similar Documents

Publication Publication Date Title
JP6042455B2 (ja) 免疫原性組成物の調製方法
JP7494276B2 (ja) 非天然アミノ酸とのポリペプチド抗原接合体
Jones Vaccines based on the cell surface carbohydrates of pathogenic bacteria
JP2022105155A (ja) 多糖類－タンパク質コンジュゲートを含む多価肺炎球菌ワクチン組成物
IE58977B1 (en) Covalently-modified neutral bacterial polysaccharides, stable covalent conjugates of such plysaccharides and immunogenic proteins, and methods of preparing such polysaccharides and conjugates
CA2897348C (en) Cycloalkyne derivatized saccharides
JP5744842B2 (ja) 髄膜炎菌と肺炎球菌との結合型ワクチン及びそれを使用する方法
Berti et al. Carbohydrate based meningococcal vaccines: past and present overview
US12053515B2 (en) Multivalent pneumococcal glycoconjugate vaccines containing emerging serotype 24F
JP2013504588A (ja) 免疫原性の高いタンパク質マトリックスワクチン
CN113164581A (zh) 纯化的肺炎链球菌荚膜多糖
BE1024282B1 (fr) Compositions immunogènes
EA044044B1 (ru) Иммуногенные композиции, содержащие конъюгаты полипептид-антиген с неприродными аминокислотами

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160107

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160108

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20160108

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20160204

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160301

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160601

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160621

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160916

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20161011

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20161109

R150 Certificate of patent or registration of utility model

Ref document number: 6042455

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250